Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 11, 2026, 3:41 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 265–288 of 6,229 matching trials from the live ClinicalTrials.gov search.
Conditions
Urinary Tract Infections
Interventions
LBP-EC01 0.1 x IV dose, LBP-EC01 0.01x IV Dose, LBP-EC01 IV Infusion Dose, Placebo, LBP-EC01, TMP/SMX
Drug
Lead sponsor
Locus Biosciences
Industry
Eligibility
18 Years to 75 Years · Female only
Enrollment
318 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
17
States / cities
Fresno, California • Lancaster, California • Los Angeles, California + 13 more
Conditions
Obesity
Interventions
CE-326,597, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 65 Years
Enrollment
41 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
12
States / cities
Anniston, Alabama • Phoenix, Arizona • Anaheim, California + 8 more
Conditions
OSA, Heart Failure, Myocardial Infarction, Arrhythmia, Cardiac
Interventions
Continuous Positive Airway Pressure
Device
Lead sponsor
Kaiser Permanente
Other
Eligibility
18 Years and older
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
Fontana, California
Conditions
Physical Activity
Interventions
HeartSteps: A just-in-time intervention for increasing physical activity among sedentary adults.
Behavioral
Lead sponsor
Kaiser Permanente
Other
Eligibility
18 Years to 75 Years
Enrollment
118 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Seattle, Washington
Conditions
Arthritis, Rheumatoid
Interventions
CNTO 136 100 mg, CNTO 136 50 mg, CNTO 136 25 mg, Placebo, Methotrexate
Drug
Lead sponsor
Centocor, Inc.
Industry
Eligibility
18 Years and older
Enrollment
187 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
8
States / cities
Aventura, Florida • Lexington, Kentucky • Frederick, Maryland + 5 more
Conditions
Postmenopausal
Interventions
Diet - higher protein, Physical activity and resistance training
Other · Behavioral
Lead sponsor
University of Arkansas, Fayetteville
Other
Eligibility
Female only
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
2
States / cities
Fayetteville, Arkansas
Conditions
Advanced Solid Tumor
Interventions
vilastobart (XTX101), Atezolizumab
Drug
Lead sponsor
Xilio Development, Inc.
Industry
Eligibility
18 Years and older
Enrollment
125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
19
States / cities
Phoenix, Arizona • Duarte, California • Encinitas, California + 16 more
Conditions
Healthy Volunteers, Chronic Kidney Disease
Interventions
IGT-303, Placebo
Drug
Lead sponsor
Ingenia Therapeutics INC
Industry
Eligibility
18 Years to 75 Years
Enrollment
94 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
4
States / cities
Chula Vista, California • Lakeland, Florida • Statesville, North Carolina + 1 more
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Successful Aging and Enrichment (SAGE)

NCT05128396
Conditions
Cognitive Health, Healthy Aging
Interventions
Cognitive Stimulation, Mindfulness training, Physical Activity, Control Group
Behavioral
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
65 Years and older
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Colorectal Cancer, Metastatic Cancer
Interventions
Floxuridine, Fluorouracil (5-FU), Conventional surgery, Radiofrequency ablation
Drug · Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2003
U.S. locations
1
States / cities
Houston, Texas
Conditions
Knee Cartilage Defects
Interventions
CARTISTEM® + Debridement, Debridement
Biological · Procedure
Lead sponsor
Medipost, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
37
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Tempe, Arizona + 30 more
Conditions
Obesity, Overeating, Food Addiction
Interventions
Intake of nutritionally diverse ultra-processed foods
Other
Lead sponsor
Oregon Research Institute
Other
Eligibility
18 Years to 65 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
Psychotic Disorders
Interventions
Person-centered planning (PCP), Community integration (CI), Illness management recovery (IMR)
Behavioral
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
290 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
1
States / cities
New Haven, Connecticut
Conditions
Diabetic Peripheral Neuropathic Pain
Interventions
RTA 901, RTA 901-Matching Placebo
Drug
Lead sponsor
Reata, a wholly owned subsidiary of Biogen
Industry
Eligibility
18 Years and older
Enrollment
209 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
75
States / cities
Mesa, Arizona • Phoenix, Arizona • Canoga Park, California + 60 more
Conditions
Non Small Cell Lung Cancer, Bladder Cancer, Renal Cell Carcinoma, Melanoma, Head and Neck Cancer, Colorectal Cancer
Interventions
PF-07921585, Sasanlimab
Biological
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
9
States / cities
Fayetteville, Arkansas • Rogers, Arkansas • Springdale, Arkansas + 4 more
Conditions
Alcohol Use Disorder
Interventions
CMND-100
Drug
Lead sponsor
Clearmind Medicine Inc.
Industry
Eligibility
18 Years to 60 Years
Enrollment
84 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
2
States / cities
New Haven, Connecticut • Baltimore, Maryland
Conditions
Covid19
Interventions
sotrovimab, Placebo to Biologic
Biological · Other
Lead sponsor
Vir Biotechnology, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
2
States / cities
Anaheim, California • Glendale, California
Terminated Phase 3 Interventional Results available

Leukemia Stem Cell Detection in Acute Myeloid Leukemia

NCT02927938
Conditions
Acute Myeloid Leukemia (AML)
Interventions
Allogeneic HCT, Consolidation chemotherapy
Procedure · Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Charlotte, North Carolina
Conditions
Williams Syndrome
Interventions
Response Inhibition Training
Behavioral
Lead sponsor
University of Wisconsin, Milwaukee
Other
Eligibility
10 Years to 17 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Conditions
Pancreatic Cancer, Ductal Adrenocarcinoma, Exocrine Pancreatic Cancer
Interventions
PCI-27483, Gemcitabine
Drug
Lead sponsor
Pharmacyclics LLC.
Industry
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2009
U.S. locations
17
States / cities
Scottsdale, Arizona • Anaheim, California • Titusville, Florida + 13 more
Conditions
Locally Advanced Bladder Urothelial Carcinoma, Locally Advanced Renal Pelvis Urothelial Carcinoma, Locally Advanced Ureter Urothelial Carcinoma, Locally Advanced Urethral Urothelial Carcinoma, Locally Advanced Urothelial Carcinoma, Metastatic Bladder Urothelial Carcinoma, Metastatic Renal Pelvis Urothelial Carcinoma, Metastatic Ureter Urothelial Carcinoma, Metastatic Urethral Urothelial Carcinoma, Metastatic Urothelial Carcinoma, Recurrent Bladder Urothelial Carcinoma, Recurrent Renal Pelvis Urothelial Carcinoma, Recurrent Ureter Urothelial Carcinoma, Recurrent Urethral Urothelial Carcinoma, Recurrent Urothelial Carcinoma, Stage III Bladder Cancer AJCC v8, Stage III Renal Pelvis Cancer AJCC v8, Stage III Ureter Cancer AJCC v8, Stage III Urethral Cancer AJCC v8, Stage IIIA Bladder Cancer AJCC v8, Stage IIIB Bladder Cancer AJCC v8, Stage IV Bladder Cancer AJCC v8, Stage IV Renal Pelvis Cancer AJCC v8, Stage IV Ureter Cancer AJCC v8, Stage IV Urethral Cancer AJCC v8, Stage IVA Bladder Cancer AJCC v8, Stage IVB Bladder Cancer AJCC v8, Unresectable Bladder Urothelial Carcinoma, Unresectable Renal Pelvis Urothelial Carcinoma, Unresectable Ureter Urothelial Carcinoma, Unresectable Urethral Urothelial Carcinoma, Unresectable Urothelial Carcinoma
Interventions
Diagnostic Laboratory Biomarker Analysis, Nivolumab, Relatlimab
Other · Biological · Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Houston, Texas
Conditions
Hodgkin Disease, Peripheral T Cell Lymphoma
Interventions
brentuximab vedotin, bendamustine, dacarbazine, nivolumab
Drug
Lead sponsor
Seagen Inc.
Industry
Eligibility
18 Years and older
Enrollment
131 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2023
U.S. locations
49
States / cities
Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 43 more
Completed Phase 1Phase 2 Interventional Results available

AMG 102 and Erlotinib for Advanced Non-Small Cell Lung Cancer

NCT01233687
Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
AMG 102 and erlotinib
Drug
Lead sponsor
Ahmad Tarhini
Other
Eligibility
18 Years and older
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Conditions
Unspecified Adult Solid Tumor, Protocol Specific
Interventions
counseling intervention, quality-of-life assessment, questionnaire administration, educational intervention
Other · Procedure
Lead sponsor
City of Hope Medical Center
Other
Eligibility
21 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
2
States / cities
Duarte, California • Baltimore, Maryland